IBT
KDNY

International Biotechnology Trust’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

International Biotechnology Trust’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-319,989
Closed -$7.41M – 76
2023
Q1 		$7.41M Sell
319,989
-20,400
-6% -$486K 2.07% 17
2022
Q4 		$8.91M Hold
340,389
– – 2.75% 12
2022
Q3 		$6.68M Buy
340,389
+334,442
+5,624% +$6.71M 2.14% 16
2022
Q2 		$340K Sell
5,947
-334,442
-98% -$5.25M 3.55% 9
2022
Q1 		$4.71M Buy
340,389
+51,000
+18% +$693K 1.06% 30
2021
Q4 		$4.71M Buy
289,389
+54,389
+23% +$774K 1.05% 30
2021
Q3 		$2.99M Buy
235,000
+64,179
+38% +$845K 0.72% 31
2021
Q2 		$2.41M Buy
+170,821
New +$2.73M 0.64% 36

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

International Biotechnology Trust's KDNY Position: Q2 2023 in Review

International Biotechnology Trust sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 319,989 shares — an estimated $7.41M sold.

International Biotechnology Trust first reported a position in KDNY in Q2 2021 and held it in 8 quarters. The position peaked at $8.91M in Q4 2022. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

  • International Biotechnology Trust reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • International Biotechnology Trust sold 319,989 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $7.41M.
  • International Biotechnology Trust first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • International Biotechnology Trust's Chinook Therapeutics, Inc. Common Stock position peaked at $8.91M in Q4 2022.
  • 185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on International Biotechnology Trust's 13F filing for Q2 2023, filed 8 Aug 2023.